BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 17347915)

  • 1. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.
    Eng CM; Fletcher J; Wilcox WR; Waldek S; Scott CR; Sillence DO; Breunig F; Charrow J; Germain DP; Nicholls K; Banikazemi M
    J Inherit Metab Dis; 2007 Apr; 30(2):184-92. PubMed ID: 17347915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.
    Hopkin RJ; Bissler J; Banikazemi M; Clarke L; Eng CM; Germain DP; Lemay R; Tylki-Szymanska A; Wilcox WR
    Pediatr Res; 2008 Nov; 64(5):550-5. PubMed ID: 18596579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.
    Sims K; Politei J; Banikazemi M; Lee P
    Stroke; 2009 Mar; 40(3):788-94. PubMed ID: 19150871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demographic characterization of Brazilian patients enrolled in the Fabry Registry.
    Martins AM; Kyosen SO; Garrote J; Marques FM; Guilhem JG; Macedo E; Sobral Neto J; Ura S
    Genet Mol Res; 2013 Jan; 12(1):136-42. PubMed ID: 23408399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.
    Schiffmann R; Warnock DG; Banikazemi M; Bultas J; Linthorst GE; Packman S; Sorensen SA; Wilcox WR; Desnick RJ
    Nephrol Dial Transplant; 2009 Jul; 24(7):2102-11. PubMed ID: 19218538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
    Wilcox WR; Oliveira JP; Hopkin RJ; Ortiz A; Banikazemi M; Feldt-Rasmussen U; Sims K; Waldek S; Pastores GM; Lee P; Eng CM; Marodi L; Stanford KE; Breunig F; Wanner C; Warnock DG; Lemay RM; Germain DP;
    Mol Genet Metab; 2008 Feb; 93(2):112-28. PubMed ID: 18037317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
    Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
    Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
    Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
    Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Musculoskeletal manifestations of Fabry disease: A retrospective study.
    Lidove O; Zeller V; Chicheportiche V; Meyssonnier V; Sené T; Godot S; Ziza JM
    Joint Bone Spine; 2016 Jul; 83(4):421-6. PubMed ID: 26697993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry disease and the skin: data from FOS, the Fabry outcome survey.
    Orteu CH; Jansen T; Lidove O; Jaussaud R; Hughes DA; Pintos-Morell G; Ramaswami U; Parini R; Sunder-Plassman G; Beck M; Mehta AB;
    Br J Dermatol; 2007 Aug; 157(2):331-7. PubMed ID: 17573884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.
    MacDermot KD; Holmes A; Miners AH
    J Med Genet; 2001 Nov; 38(11):750-60. PubMed ID: 11694547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
    Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
    Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.
    Politei JM; Cabrera G; Amartino H; Valdez R; Masllorens F; Ripeau D; Antongiovanni N; Soliani A; Luna P; Cedrolla M; Fernandez S; Fainboim A
    Int J Clin Pract; 2013 Jan; 67(1):66-72. PubMed ID: 23241050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS).
    Barba-Romero MÁ; Rivera-Gallego A; Pintos-Morell G;
    Int J Clin Pract; 2011 Aug; 65(8):903-10. PubMed ID: 21679285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution of the initial manifestations and renal involvement of chinese patients with classical and late-onset Fabry disease at different sexes and ages.
    Guo W; Xie Y; Ji P; Li S; Cai G; Chen X
    BMC Nephrol; 2023 Apr; 24(1):90. PubMed ID: 37020293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry disease, novel GLA mutation and severe cardiac phenotype.
    San Román-Monserrat I; Moreno-Flores V; López-Cuenca D; Rodríguez-González-Herrero E; Guillén-Navarro E; Rodríguez-González-Herrero B; Alegría-Fernández M; Poza-Cisneros G; Piñero-Fernández JA; Sornichero-Martínez J; Gimeno-Blanes JR
    Med Clin (Barc); 2014 Jun; 142(11):497-504. PubMed ID: 24679964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.
    Whybra C; Kampmann C; Willers I; Davies J; Winchester B; Kriegsmann J; Brühl K; Gal A; Bunge S; Beck M
    J Inherit Metab Dis; 2001 Dec; 24(7):715-24. PubMed ID: 11804208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
    Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
    Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey of the pain experienced by males and females with Fabry disease.
    Gibas AL; Klatt R; Johnson J; Clarke JT; Katz J
    Pain Res Manag; 2006; 11(3):185-92. PubMed ID: 16960635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.